Fig. 1From: An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteriaPatient population. CKD chronic kidney disease (defined as eGFR < 60 mL/min/1.73 m2 or eGFR ≥ 60 mL/min/1.73 m.2 and albuminuria ≥ 30 mg/g; RCT randomized controlled trial; T2DM, type-2 diabetes mellitus [28, 29]Back to article page